Page last updated: 2024-08-25

5-fluoropyrimidine and gefitinib

5-fluoropyrimidine has been researched along with gefitinib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Magné, N; Marchetti, S; Milano, G; Renée, N; Tiffon, C	1
Bridgewater, J; Glynne-Jones, R; Harrison, M; Propper, D; Stebbing, J	1

Trials

1 trial(s) available for 5-fluoropyrimidine and gefitinib

Article	Year
A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study). British journal of cancer, 2008, Feb-26, Volume: 98, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Pyrimidines; Quinazolines	2008

Article

Year

A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).

British journal of cancer, 2008, Feb-26, Volume: 98, Issue:4

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Pyrimidines; Quinazolines

2008

Other Studies

1 other study(ies) available for 5-fluoropyrimidine and gefitinib

Article	Year
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-15, Volume: 9, Issue:13 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Primers; Floxuridine; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Models, Chemical; Polymerase Chain Reaction; Pyrimidines; Quinazolines; RNA; RNA, Messenger; Time Factors; Transcription, Genetic	2003

Article

Year

ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-15, Volume: 9, Issue:13

Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Primers; Floxuridine; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Models, Chemical; Polymerase Chain Reaction; Pyrimidines; Quinazolines; RNA; RNA, Messenger; Time Factors; Transcription, Genetic

2003